Climb Bio (CLYM) AI Stock Analysis

• Market Cap: $82.99M
• Dividend Yield: N/A
• Average Volume (3M): 153.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: -61.95%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -2.13
• Shares Outstanding: 67,475,395
• 10 Day Avg. Volume: 111,561
• 30 Day Avg. Volume: 153,615
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.35
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 713.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Climb Bio's stock score is low due to significant financial challenges, including negative profitability and cash flow. Technical indicators show a bearish trend, and valuation metrics reflect the company's developmental stage with no profit or dividend. Strong cash reserves provide a buffer but are insufficient to offset the broader financial risks.

Positive Factors

Financial Position

CLYM reported a cash position of approximately $213 million, providing financial runway through 2027.

Pipeline Expansion

CLYM has expanded their B-cell focused pipeline by in-licensing anti-APRIL antibody CLYM116 from China-based Mabworks Biotech.

Regulatory Approval

The company has received FDA clearance to initiate a Phase 2 study of budo in primary membranous nephropathy following compelling data from a Phase 1b trial.

Negative Factors

Clinical Development Risks

Preclinical results for the subcutaneous formulation of budo are expected and the company plans to advance this program into the clinic.

Market Competition

The familiar antibody format and commercial scalability of budo offer an attractive option that balances efficacy and safety in the competitive CD19-targeting space.

Climb Bio Business Overview & Revenue Model

Company Description

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

How the Company Makes Money

Climb Bio Financial Statement Overview

Summary

Climb Bio's financial performance reflects its developmental stage in biotechnology. The company faces significant losses without revenue generation, resulting in a low income statement score of 25. Its balance sheet is stronger with a score of 55 due to low debt and substantial cash reserves, yet its cash flow score is 35, indicating reliance on financing activities and potential cash burn risks.

Income Statement

Climb Bio has experienced consistent losses with no revenue generation, typical for a biotechnology company in development stages. The company's EBIT and EBITDA margins are negative, reflecting ongoing operational expenses without offsetting revenue. The net income is consistently negative, highlighting significant operational challenges.

Balance Sheet

Climb Bio maintains a strong equity position with low debt, as indicated by a low debt-to-equity ratio. The company has substantial cash reserves, enhancing its financial stability. However, the lack of revenue generation and continuous accumulation of losses could impact long-term sustainability if not addressed.

Cash Flow

The company has negative operating and free cash flows, which are expected for a biotech firm without commercial products. The free cash flow has not shown growth, and reliance on financing activities is evident. This indicates potential cash burn risks if external funding sources diminish.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
-82.02M	-40.27M	-45.13M	-35.67M	-20.93M
	EBITDA
-30.36M	-40.27M	-45.13M	-35.67M	-11.77M
	Net Income Common Stockholders
-73.90M	-35.12M	-45.24M	-47.48M	-20.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
150.92M	106.80M	123.57M	136.48M	20.49M
	Total Assets
217.19M	110.47M	134.99M	173.24M	24.63M
	Total Debt
532.00K	349.00K	480.00K	0.00	0.00
	Net Debt
-86.70M	-92.76M	-43.10M	-46.92M	-20.49M
	Total Liabilities
5.31M	2.87M	6.28M	6.04M	3.06M
	Stockholders Equity
211.88M	107.60M	128.72M	167.20M	21.57M
Cash Flow		Free Cash Flow
-15.56M	-20.60M	-37.37M	-36.07M	-14.10M
	Operating Cash Flow
-15.56M	-20.60M	-37.37M	-36.07M	-14.10M
	Investing Cash Flow
-121.09M	68.98M	34.44M	-114.97M	8.08M
	Financing Cash Flow
130.73M	841.00K	0.00	177.23M	4.92M

Climb Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLYM, the sentiment is Negative. The current price of 1.23 is below the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.32, and below the 200-day MA of 3.79, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.45 is Neutral, neither overbought nor oversold. The STOCH value of 39.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLYM.

Climb Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.35B	3.41	-40.48%	2.89%	17.92%	2.25%
ORMP	47 Neutral	$91.51M	21.10	-12.29%	―	-100.00%	―
IMUX	41 Neutral	$107.32M	―	-424.44%	―	―	51.02%
CCCC	41 Neutral	$115.03M	―	-45.58%	―	71.44%	43.22%
CLYM	40 Underperform	$82.99M	―	-46.26%	―	―	-61.95%
VOR	33 Underperform	$87.11M	―	-94.52%	―	―	2.98%

Climb Bio Corporate Events

Climb Bio Expands Board with New Director Appointments

On March 27, 2025, Climb Bio, Inc. experienced changes in its board of directors with the resignation of Simon Tate and the decision of Adam Rosenberg not to seek re-election. Both directors clarified that their decisions were not due to disagreements with the company’s operations or policies. On March 28, 2025, the board expanded from seven to eight members, electing Alexander (Bo) Cumbo and Kimberlee (Kim) Drapkin as new directors. Cumbo and Drapkin will serve in various committee roles and receive compensation in line with the company’s non-employee director compensation policy. These changes are part of the company’s ongoing governance adjustments and may influence its strategic direction.